Accelerated Degradation of Acetylcholine Receptor from Cultured Rat Myotubes with Myasthenia Gravis Sera and Globulins

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1977 May 1

PMID 266734

Citations 33

Authors

S H Appel

R Anwyl

M W McAdams

S Elias

Affiliations

Soon will be listed here.

Abstract

Altered geometry of the neuromuscular junction and a decreased number of acetylcholine receptors appear responsible for the defect of neuromuscular transmission in myasthenia gravis. We have used cultured rat myotubes as a model to study in vitro the potential role of myasthenic globulins in the pathological process. Acetylcholine receptor content was assayed by the extent of 125I-labeled alpha-bungarotoxin binding, and acetylcholine receptor function was assayed by the sensitivity to acetylcholine iontophoresis. The half-life of the acetylcholine receptor was 18.5 hr in the presence or absence of control sera. Myasthenic sera and globulins produced a gradual reduction in acetylcholine receptors, as assessed by biochemical and electrophysiological techniques. The half-life in the presence of myasthenic sera was 6 hr. The accelerated turnover was unaffected by puromycin but was slowed by lowered temperature (18-20 degrees), interference with energy metabolism (2,4-dinitrophenol), and interference with cytoskeletal structures (colchicine and cytochalasin B). We found no electrophysiological evidence to suggest globulin blockade of acetylcholine access to the acetylcholine receptor. Our observations suggest that circulating globulins in myasthenia gravis may contribute to the functional defects of neuromuscular transmission by accelerating the rate of internationalization and degradation of surface membrane acetylcholine receptors.

Citing Articles

Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy.

Fewou S, Rupp A, Nickolay L, Carrick K, Greenshields K, Pediani J J Clin Invest. 2012; 122(3):1037-51.

PMID: 22307327 PMC: 3287221. DOI: 10.1172/JCI59110.

Cholesterol modulates the rate and mechanism of acetylcholine receptor internalization.

Borroni V, Barrantes F J Biol Chem. 2011; 286(19):17122-32.

PMID: 21357688 PMC: 3089556. DOI: 10.1074/jbc.M110.211870.

Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Graus Y, De Baets M Immunol Res. 1993; 12(1):78-100.

PMID: 7685805 DOI: 10.1007/BF02918370.

Experimental myasthenia gravis. A murine system.

BERMAN P, Patrick J J Exp Med. 1980; 151(1):204-23.

PMID: 7350247 PMC: 2185769. DOI: 10.1084/jem.151.1.204.

Acetylcholine receptor in rabbit thymus: antigenic similarity between acetylcholine receptors of muscle and thymus.

Ueno S, Wada K, Takahashi M, Tarui S Clin Exp Immunol. 1980; 42(3):463-9.

PMID: 7214741 PMC: 1537169.

References

Flier J, Kahn C, Jarrett D, Roth J . Characterization of antibodies to the insulin receptor: a cause of insulin-resistant diabetes in man. J Clin Invest. 1976; 58(6):1442-9. PMC: 333316. DOI: 10.1172/JCI108600. View

Merlie J, Changeux J, Gros F . Acetylcholine receptor degradation measured by pulse chase labelling. Nature. 1976; 264(5581):74-6. DOI: 10.1038/264074a0. View

Berg D, Hall Z . Loss of alpha-bungarotoxin from junctional and extrajunctional acetylcholine receptors in rat diaphragm muscle in vivo and in organ culture. J Physiol. 1975; 252(3):771-89. PMC: 1348494. DOI: 10.1113/jphysiol.1975.sp011169. View

Loor F, Forni L, Pernis B . The dynamic state of the lymphocyte membrane. Factors affecting the distribution and turnover of surface immunoglobulins. Eur J Immunol. 1972; 2(3):203-12. DOI: 10.1002/eji.1830020304. View

Bender A, Ringel S, Engel W, Daniels M, Vogel Z . Myasthenia gravis: a serum factor blocking acetylcholine receptors of the human neuromuscular junction. Lancet. 1975; 1(7907):607-9. DOI: 10.1016/s0140-6736(75)91886-3. View

UNANUE E, Karnovsky M, Engers H . Ligand-induced movement of lymphocyte membrane macromolecules. 3. Relationship between the formation and fate of anti-Ig-surface Ig complexes and cell metabolism. J Exp Med. 1973; 137(3):675-89. PMC: 2139388. DOI: 10.1084/jem.137.3.675. View

Devreotes P, Fambrough D . Acetylcholine receptor turnover in membranes of developing muscle fibers. J Cell Biol. 1975; 65(2):335-58. PMC: 2109417. DOI: 10.1083/jcb.65.2.335. View

Sanders D, Schleifer L, Eldefrawi M, Norcross N, Cobb E . An immunologically induced defect of neuromuscular transmission in rats and rabbits. Ann N Y Acad Sci. 1976; 274:319-36. DOI: 10.1111/j.1749-6632.1976.tb47695.x. View

Albuquerque E, Rash J, Mayer R, Satterfield J . An electrophysiological and morphological study of the neuromuscular junction in patients with myasthenia gravis. Exp Neurol. 1976; 51(3):536-63. DOI: 10.1016/0014-4886(76)90179-5. View

10.

Almon R, Andrew C, Appel S . Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science. 1974; 186(4158):55-7. DOI: 10.1126/science.186.4158.55. View

11.

de Petris S . Inhibition and reversal of capping by cytochalasin B, vinblastine and colchicine. Nature. 1974; 250(461):54-6. DOI: 10.1038/250054a0. View

12.

Fambrough D, Drachman D, Satyamurti S . Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science. 1973; 182(4109):293-5. DOI: 10.1126/science.182.4109.293. View

13.

Patrick J, Lindstrom J . Autoimmune response to acetylcholine receptor. Science. 1973; 180(4088):871-2. DOI: 10.1126/science.180.4088.871. View

14.

Engel A, Santa T . Histometric analysis of the ultrastructure of the neuromuscular junction in myasthenia gravis and in the myasthenic syndrome. Ann N Y Acad Sci. 1971; 183:46-63. DOI: 10.1111/j.1749-6632.1971.tb30741.x. View

15.

Engel A, Tsujihata M, Lindstrom J, Lennon V . The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study. Ann N Y Acad Sci. 1976; 274:60-79. DOI: 10.1111/j.1749-6632.1976.tb47676.x. View

16.

Albuquerque E, Lebeda F, Appel S, Almon R, Kauffman F, Mayer R . Effects of normal and myasthenic serum factors on innervated and chronically denervated mammalian muscles. Ann N Y Acad Sci. 1976; 274:475-92. DOI: 10.1111/j.1749-6632.1976.tb47709.x. View

17.

Seybold M, LAMBERT E, Lennon V, Lindstrom J . Experimental autoimmune myasthenia: clinical, neurophysiologic, and pharmacologic aspects. Ann N Y Acad Sci. 1976; 274:275-82. DOI: 10.1111/j.1749-6632.1976.tb47692.x. View

18.

Lindstrom J, Lennon V, Seybold M, Whittingham S . Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects. Ann N Y Acad Sci. 1976; 274:254-74. DOI: 10.1111/j.1749-6632.1976.tb47691.x. View

19.

Poste G, Papahadjopoulos D, Nicolson G . Local anesthetics affect transmembrane cytoskeletal control of mobility and distribution of cell surface receptors. Proc Natl Acad Sci U S A. 1975; 72(11):4430-4. PMC: 388735. DOI: 10.1073/pnas.72.11.4430. View

20.

Toyka K, Brachman D, Pestronk A, Kao I . Myasthenia gravis: passive transfer from man to mouse. Science. 1975; 190(4212):397-9. DOI: 10.1126/science.1179220. View